Investigational drug · Phase 2
AZD5148
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Clostridioides Difficile Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "AZD5148"
First trial start
2025
Dec 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD5148", any sponsor or status.
Conditions studied
As listed on its trial records.
- Clostridioides Difficile Infection
Approved drugs for the same conditions: C. difficile infection · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD5148" as an intervention, largest first.
- Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal AntibodyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07285213 · 230 participants (planned) · Start Dec 10, 2025 · Primary completion Apr 20, 2027
Drug: AZD5148 · For: Clostridioides Difficile Infection
Sites: Phoenix, Arizona; Chula Vista, California; Sacramento, California · 117 sites in all
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy AdultsCompleted
AstraZenecaAstraZeneca (AZN)
NCT06469151 · 84 participants · Start Jun 24, 2024 · Primary completion Oct 22, 2025
Drug: AZD5148; Placebo · For: Healthy Participants
Sites: Anniston, Alabama; Glendale, California; Baltimore, Maryland · 4 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06639997 · 16 participants · Start Oct 31, 2024 · Primary completion Dec 25, 2025
Drug: AZD5148; Placebo · For: Clostridioides Difficile Infection
Sites: Sumida-ku, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates.
Mahool KA, Nguyen E, Godfrey V, et al. · J Infect Dis 2025
- The monoclonal antibody AZD5148 confers broad protection against TcdB-diverse Clostridioides difficile strains in mice.
Peritore-Galve FC, Kroh HK, Shupe JA, et al. · PLoS Pathog 2025
Also in development for Clostridioides Difficile Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.